Lantheus Holdings completed 2025 with full-year revenue of $1.54 billion and adjusted earnings per share of $6.08, though fourth-quarter results reflected softening demand in key product lines. The medical imaging company reported Q4 revenue of $406.8 million with adjusted EPS of $1.67, as PYLARIFY sales declined 9.7% during the quarter, signaling headwinds in the diagnostic imaging market.
The company announced a significant strategic realignment, indicating plans to concentrate resources on its PET radiodiagnostics business while exploring value-maximizing options for its radiotherapeutic assets. This repositioning reflects management's assessment of market opportunities and capital allocation priorities as the company navigates evolving demand in nuclear medicine imaging and therapy.
Lantheus projects substantial product advancement in 2026, anticipating up to four FDA approvals throughout the year. The company provided 2026 guidance of $1.4-1.45 billion in revenue and adjusted EPS of $5.00-5.25, suggesting a modest revenue decline but indicating management confidence in pipeline progression and market positioning. The outlook reflects expectations for new product contributions alongside existing commercial operations.